New data show investigational migraine therapy demonstrates effective treatment of migraine-associated neck and sinus pain Pozen (Nasdaq POZN) 6.73 : POZN and GSK announce an investigational migraine treatment demonstrates effective treatment of migraine-associated neck pain/discomfort and sinus pain/pressure, according to new data presented at the Annual Meeting of the American Headache Society. In addition, use of the compound was statistically superior in producing pain-free rates as early as 30 minutes. Furthermore, significantly more patients reached pain-free status at two hours; this result was sustained for 24 hours without the use of additional medicine. This single tablet combination therapy, currently under review with the FDA under the proposed trade name Trexima, contains sumatriptan 85 mg, as the succinate salt, formulated with RT Technology, and naproxen sodium 500 mg.

POZN is trading up 5.65% to $7.11 on Nasdaq